Anti-EGFR enhanced neoadjuvant immunotherapy versus neoadjuvant immunochemotherapy for locally advanced oral squamous cell carcinoma
NAIC demonstrates superior pathologic responses and survival benefits compared to both NAI-CTX and NAC, establishing it as a highly promising neoadjuvant strategy for locally advanced OSCC.
Authors
- Qiufeng Jin
- Qigen Fang (ORCID: https://orcid.org/0000-0002-7303-1030)
- Wei Du (ORCID: https://orcid.org/0000-0002-7410-9194)
- Peng Li (ORCID: https://orcid.org/0000-0003-3571-1550)
- Mingwei Su
Institutions
- Henan Cancer Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-11-20
- DOI
- https://doi.org/10.3389/fimmu.2025.1669368
- Citations
- 1
- Primary Topic
- Head and Neck Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.85